Expertise in
4
conditions

Maryline Barrie

264 Rue Saint Pierre, 
Marseille, FR 
Expertise in
4
conditions
264 Rue Saint Pierre, 
Marseille, FR 

Overview

Maryline Barrie practices practicing medicine in Marseille, France.

Ms. Barrie is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Glioma, Gliomatosis Cerebri, Astrocytoma, and Glioblastoma.

She is actively involved in clinical research, co-authoring 29 peer reviewed articles and participating in 3 clinical trials.

Gender

Female

Locations

264 Rue Saint Pierre, Marseille, 13005, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Phase III Randomised Trial Evaluating Treatment Intensification With Temozolomide in Adults With a Glioblastoma
Phase III Randomised Trial Evaluating Treatment Intensification With Temozolomide in Adults With a Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Drug
Study Drugs: Intensified Protocol, Stupp Protocol
Study Phase: Phase 3
Study of the Efficacy and Safety of Perampanel in Combination in Glioma-refractory Epilepsy
Study of the Efficacy and Safety of Perampanel in Combination in Glioma-refractory Epilepsy
Enrollment Status: Withdrawn
Publish Date: June 27, 2022
Intervention Type: Drug
Study Phase: Not Applicable
An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway
An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway
Enrollment Status: Terminated
Publish Date: May 21, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

29 Total Publications

Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomas.
Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomas.
Journal: Journal of neuro-oncology
Published: August 26, 2025

Frequently Asked Questions about Maryline Barrie

Is Maryline Barrie a top-rated expert for Glioma?

MediFind is an objective health platform that identifies experts based on real-world data. Maryline Barrie is classified as an Advanced expert for Glioma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Maryline Barrie participate in research or clinical trials?

Yes. Maryline Barrie has published 29 articles and abstracts on conditions like Glioma. You can view a list of Maryline Barrie's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Barrie's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile